Clinical Trial Update: A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum [Phase 2]

View source ↗

Summary

A Phase II open-label study of Xilonix in Pyoderma Gangrenosum has completed, according to Janssen's clinical trial update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• Xilonix

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Pyoderma Gangrenosum | Phase 2 | Status: COMPLETED